References
- Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38:781–782.
- Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41:1801–1803.
- Sharma RK, Stevens BR, Obukhov AG, et al. ACE2 (angiotensin-converting enzyme 2) in cardiopulmonary diseases: ramifications for the control of SARS-CoV-2. Hypertension. 2020;76:651–661.
- Kreutz R, El-Hady EA, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020;116:1688–1699.
- Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75:1382–1385.
- Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431–2440.
- Lopes RD, Macedo AVS, de Barros E Silva PGM, et al.; BRACE CORONA investigators. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-The BRACE CORONA Trial. Am Heart J. 2020;226:49–59.
- Mancia G. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial. Cardiovasc Res. 2020;116:e198–e199.
- Savarese G, Benson L, Sundström J, et al. Association between renin-angiotensin-aldosterone system inhibitor use and covid-19 hospitalization and death: a 1.4 million patient nation-wide registry analysis. Eur J Heart Failure. 2020; in press. DOI: 10.1002/ejhf.2060
- Pinto-Sietsma S-J, Flossdorf M, Buchholtz VR, et al. Antihypertensive drugs in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6:415–416.
- Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441–2448.
- Barbieri A, Robinson N, Palma G, et al. Can beta-2-adrenergic pathway be a new target to combat SARS-COV-2 hyperinflammatory syndrome? Lessons learned from cancer. Front Immunol. 2020;11:588724.
- Yan F, Huang F, Xu J, et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly Covid-19 patients. Cell Discov. 2020;6:77.
- Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand. 2003;177:385–390.
- Kubon C, Mistry NB, Grundvold I, et al. The role of beta-blockers in the treatment of chronic heart failure. Trends Pharmacol Sci. 2011;32:206–212.
- Vasanthakumar N. Beta-adrenergic blockers as a potential treatment for Covid-19 patients. BioEssays. 2020;42:2000094.
- Heriansya T, Chomsy IN, Febrianda R, et al. The potential benefit of beta-blockers for the management of Covid-19 protocol therapy-induced QT prolongation: a literature review. Sci. Pharm. 2020; 88:0055.
- Ayoub N. Carvedilol as a potential addition to the Covid-19 therapeutic arsenal. Int J Pharmacy Pharm Sci. 2020;12:87–89.